MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.53 -0.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.45

Максимум

20.7

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+90.59% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	672M 1.8B
Предишно отваряне	21.35
Предишно затваряне	20.53

Настроения в новините

By Acuity

43%

57%

112 / 361 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.01.2026 г., 23:29 ч. UTC

Горещи акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

18.01.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Standalone Plan Offers Clear Path to Valuation of More Than Y40,000 a Share by 2028

18.01.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Opposing Toyota Fudosan's Revised Tender Offer for Toyota Industries

18.01.2026 г., 23:55 ч. UTC

Пазарно говорене

Oil Falls as Middle East Tensions Continue to Fade -- Market Talk

18.01.2026 г., 23:40 ч. UTC

Пазарно говорене

Precious Metals Climb After Trump Threatens Europe With Tariffs Over Greenland -- Market Talk

18.01.2026 г., 22:29 ч. UTC

Пазарно говорене

Miners Seen Extending Rally as Generalist Investors Warm to Sector -- Market Talk

18.01.2026 г., 21:03 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

18.01.2026 г., 21:03 ч. UTC

Пазарно говорене

More Australian Voters Switch Away From Major Parties -- Market Talk

18.01.2026 г., 19:46 ч. UTC

Пазарно говорене

FX Markets Taking Latest Trump Tariff Threat Calmly -- Market Talk

17.01.2026 г., 15:06 ч. UTC

Придобивния, сливания и поглъщания

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17.01.2026 г., 03:10 ч. UTC

Придобивния, сливания и поглъщания

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16.01.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16.01.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 21:48 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16.01.2026 г., 21:41 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16.01.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16.01.2026 г., 20:44 ч. UTC

Печалби

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16.01.2026 г., 20:42 ч. UTC

Пазарно говорене

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16.01.2026 г., 20:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16.01.2026 г., 19:12 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

90.59% нагоре

12-месечна прогноза

Среден 39.11 USD 90.59%

Висок 56 USD

Нисък 27 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

112 / 361 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.